These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

464 related items for PubMed ID: 23219661

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
    Despierre E, Yesilyurt BT, Lambrechts S, Johnson N, Verheijen R, van der Burg M, Casado A, Rustin G, Berns E, Leunen K, Amant F, Moerman P, Lambrechts D, Vergote I, EORTC GCG and EORTC GCG Translational Research Group.
    Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
    [Abstract] [Full Text] [Related]

  • 3. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
    Konopka B, Janiec-Jankowska A, Kwiatkowska E, Najmoła U, Bidziński M, Olszewski W, Goluda C.
    Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
    [Abstract] [Full Text] [Related]

  • 4. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA.
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [Abstract] [Full Text] [Related]

  • 5. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X, Dong Y, Zhang XM, Liang Y, Zhang Y, Meng YT, Wang Y, Wang W, Nong L, Li T, Liao QP.
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [Abstract] [Full Text] [Related]

  • 6. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN, Lin MC, Tseng LH, Chiang YC, Lin LI, Lin YF, Huang HY, Kuo KT.
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [Abstract] [Full Text] [Related]

  • 7. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.
    Int J Clin Exp Pathol; 2014 Mar; 7(9):5927-39. PubMed ID: 25337237
    [Abstract] [Full Text] [Related]

  • 8. Molecular pathology of endometrial carcinoma.
    Matias-Guiu X, Prat J.
    Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A, Willén R, Bendahl PO, Nilbert M, Borg A.
    Cancer; 2002 May 01; 94(9):2369-79. PubMed ID: 12015762
    [Abstract] [Full Text] [Related]

  • 11. PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.
    McIntyre JB, Nelson GS, Ghatage P, Morris D, Duggan MA, Lee CH, Doll CM, Köbel M.
    Gynecol Oncol; 2014 Jan 01; 132(1):188-93. PubMed ID: 24262879
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
    Zheng H, Wang Y, Tang C, Jones L, Ye H, Zhang G, Cao W, Li J, Liu L, Liu Z, Zhang C, Lou F, Liu Z, Li Y, Shi Z, Zhang J, Zhang D, Sun H, Dong H, Dong Z, Guo B, Yan HE, Lu Q, Huang X, Chen SY.
    Cancer Genomics Proteomics; 2016 Jan 01; 13(3):231-8. PubMed ID: 27107065
    [Abstract] [Full Text] [Related]

  • 15. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
    Ishikawa M, Nakayama K, Nakamura K, Ono R, Yamashita H, Ishibashi T, Minamoto T, Iida K, Razia S, Ishikawa N, Kyo S.
    Hum Pathol; 2019 Mar 01; 85():92-100. PubMed ID: 30448219
    [Abstract] [Full Text] [Related]

  • 16. Identification of molecular targets in vulvar cancers.
    Palisoul ML, Mullen MM, Feldman R, Thaker PH.
    Gynecol Oncol; 2017 Aug 01; 146(2):305-313. PubMed ID: 28536037
    [Abstract] [Full Text] [Related]

  • 17. Molecular approaches for classifying endometrial carcinoma.
    Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A, Matias-Guiu X.
    Gynecol Oncol; 2017 Apr 01; 145(1):200-207. PubMed ID: 28040204
    [Abstract] [Full Text] [Related]

  • 18. Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma.
    Kang S, Seo SS, Chang HJ, Yoo CW, Park SY, Dong SM.
    Int J Gynecol Cancer; 2008 Apr 01; 18(6):1339-43. PubMed ID: 18221484
    [Abstract] [Full Text] [Related]

  • 19. Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer.
    Malentacchi F, Turrini I, Sorbi F, Projetto E, Castiglione F, Fambrini M, Petraglia F, Pillozzi S, Noci I.
    Oncol Rep; 2019 Mar 01; 41(3):1560-1574. PubMed ID: 30569174
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.